SMAM
SYRE icon

Sugar Maple Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Sugar Maple Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-180
Closed -$4.19K – 420
2024
Q4 		$4.19K Buy
+180
New +$5.28K ﹤0.01% 237

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sugar Maple Asset Management's SYRE Position: Q1 2025 in Review

Sugar Maple Asset Management sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 180 shares — an estimated $4.19K sold.

Sugar Maple Asset Management first reported a position in SYRE in Q4 2024 and held it in 1 quarter. The position peaked at $4.19K in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Sugar Maple Asset Management reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sugar Maple Asset Management sold 180 Spyre Therapeutics shares in Q1 2025, an estimated $4.19K.
  • Sugar Maple Asset Management first reported a position in Spyre Therapeutics in Q4 2024 and held it in 1 quarter.
  • Sugar Maple Asset Management's Spyre Therapeutics position peaked at $4.19K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Sugar Maple Asset Management's 13F filing for Q1 2025, filed 10 Apr 2025.